Boscalid shows increased thyroxin‐glucuronidation in rat but not in human hepatocytes in vitro
Journal of Applied Toxicology · 2023
DOI: 10.1002/jat.4427 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Toxicology, 2023. Verfasst von Christiane Wiemann und 5 weiteren Autor:innen. Beteiligte Einrichtung: BASF Oesterreich GmbH, Vienna, Austria. Hauptthemen laut MEDLINE: Thyroxine, Microsomes, Liver. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The fungicide boscalid induces thyroid histopathological and hormone effects in the rat, secondary to liver enzyme induction. To assess the human relevance of liver enzyme induction presumably leading to thyroid hormone disruption, a species comparative in vitro study on T4‐glucuronidation was conducted. Currently, no guidelines how to evaluate Phase II induction are in place. Therefore, we investigated the optimal conditions to evaluate Phase I and Phase II induction potential of boscalid in primary rat (PRH) and human (PHH) hepatocytes. Endpoints included mRNA gene expression and enzyme activities (cytochrome P450 isozymes [CYPs] and uridine diphosphate‐glucuronosyltransferases [UGTs]), measured after 3 (D3) and 7 (D7) days of exposure to reference compounds and to 5, 10, and 20 μM boscalid, focusing on T4‐glucuronidation. Basal CYP activities and T4 glucuronidation were similar or higher on D7 than D3. The highest induction responses of CYPs were on D3, whereas UGT induction and T4‐glucuronidation increases were highest on D7. Boscalid induced CYP1A, CYP2B, and CYP3A mRNA and/or increased related activities in PRH and PHH. Species differences in the induction pattern of UGT genes by reference inducers (ß‐naphthoflavone [BNF], 5‐pregnen‐3ß‐ol‐20‐one‐16α‐carbonitirile [PCN], rifampicin [RIF], and phenobarbital [PB]) and boscalid were seen: UGT1A1, UGT1A3, and UGT1A9 were predominantly induced in PHH, while UGT2B1 was predominantly induced in PRH. Basal activity levels for T4‐glucuronidation were very low in humans and an order of magnitude higher in rat, for this reason increases in activities were assessed as delta activity to the control. Significant increases in T4‐glucuronidation occurred with boscalid in rat but not in human hepatocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BASF Oesterreich GmbH, Vienna, Austria.
- BASF SE, Ludwigshafen, Germany.
- KaLy-Cell SAS, Plobsheim, France.
ORCID-Profile: Christiane Wiemann
Zitieren
APA
Wiemann, C., Melching-Kollmuss, S., Hambruch, N., Wiss, L., Stauber, F., & Richert, L. (2023). Boscalid shows increased thyroxin‐glucuronidation in rat but not in human hepatocytes in vitro. Journal of Applied Toxicology. https://doi.org/10.1002/jat.4427
Vancouver
Wiemann C, Melching-Kollmuss S, Hambruch N, Wiss L, Stauber F, Richert L. Boscalid shows increased thyroxin‐glucuronidation in rat but not in human hepatocytes in vitro. Journal of Applied Toxicology. 2023. doi:10.1002/jat.4427
BibTeX
@article{Wiemann2023,
author = {Wiemann, Christiane and Melching-Kollmuss, Stephanie and Hambruch, Nina and Wiss, Lucille and Stauber, Franz and Richert, Lysiane},
title = {Boscalid shows increased thyroxin‐glucuronidation in rat but not in human hepatocytes in vitro},
journal = {Journal of Applied Toxicology},
year = {2023},
doi = {10.1002/jat.4427}
}
EUVIMED